Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Expenses: 2017-2025

Historic Accumulated Expenses for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $32.4 million.

  • Crinetics Pharmaceuticals' Accumulated Expenses rose 23.70% to $32.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.4 million, marking a year-over-year increase of 23.70%. This contributed to the annual value of $28.9 million for FY2024, which is 98.99% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Accumulated Expenses of $32.4 million as of Q3 2025, which was up 48.64% from $21.8 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Accumulated Expenses ranged from a high of $32.4 million in Q3 2025 and a low of $3.2 million during Q1 2021.
  • Moreover, its 3-year median value for Accumulated Expenses was $16.6 million (2025), whereas its average is $18.5 million.
  • Data for Crinetics Pharmaceuticals' Accumulated Expenses shows a peak YoY skyrocketed of 137.03% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Accumulated Expenses stood at $6.6 million in 2021, then spiked by 37.84% to $9.1 million in 2022, then surged by 59.86% to $14.5 million in 2023, then soared by 98.99% to $28.9 million in 2024, then grew by 23.70% to $32.4 million in 2025.
  • Its Accumulated Expenses stands at $32.4 million for Q3 2025, versus $21.8 million for Q2 2025 and $16.6 million for Q1 2025.